Rheumatoid arthritis

JAK inhibitor wins in head to head with abatacept

Upadactinib has been shown to have a superior efficacy to abatacept in patients with rheumatoid arthritis refractory to previous biologic therapy. The international SELECT-CHOICE trial randomised 612 patients from 120 sites across 28 countries including Australia to either the oral JAK1 inhibitor or IV abatacept Patients in the upadacitinib group also received IV placebo and ...

Already a member?

Login to keep reading.

© 2021 the limbic